|
See related Lamictal tab information |
|
|
|
Manufacturer |
GlaxoSmithKline |
|
Distributor |
Zuellig |
|
Contents |
Lamotrigine |
|
Indications |
Listed in Dosage.
Click to view Lamictal detailed prescribing infomation |
|
Dosage |
Prevention of mood episodes in bipolar disorder, predominantly by preventing depressive episodes Adult ≥18 yr Adjunct therapy w/ Na valproate 12.5 mg (25 mg alternate days) for 2 wk, then 25 mg once daily for 2 wk, then 50 mg once daily or 2 divided doses for 1 wk. Target stabilization: 100-200 mg once daily or 2 divided doses. Adjunct therapy w/ phenytoin, carbamazepine, phenobarb, primidone 50 mg once daily for 2 wk, then 100 mg in 2 divided doses for 2 wk, then 200 mg in 2 divided doses for 1 wk. Target stabilization: 300-400 mg/day in 2 divided doses. Monotherapy or adjunct therapy w/ drugs that do not significantly inhibit or induce lamotrigine glucuronidation 25 mg once daily for 2 wk, then 50 mg once daily or 2 divided doses for 2 wk, then 100 mg once daily or 2 divided doses for 1 wk. Target stabilization: 200 mg once daily or 2 divided doses. Adjunctive or monotherapy in the treatment of epilepsy, for partial & generalized seizures, including tonic-clonic seizures & seizures associated w/ Lennox-Gastaut syndrome Adult (>18 yr) & adolescents (12-18 yr) Monotherapy 25 mg once daily for 2 wk, then 50 mg once a day for 2 wk. Maintenance: 100-200 mg (once a day or 2 divided doses). Add-on therapy w/ Na valproate 12.5 mg (25 mg alternate days) for 2 wk, then 25 mg once daily for 2 wk. Maintenance: 100-200 mg/day once a day or in 2 divided doses. Add-on therapy w/ phenytoin, carbamazepine, primidone & phenobarb 50 mg once a day for 2 wk, then 100 mg/day in 2 divided doses for 2 wk. Maintenance: 200-400 mg/day in 2 divided doses. Add-on therapy w/ drugs that do not significantly inhibit or induce lamotrigine glucuronidation 25 mg once daily for 2 wk then 50 mg once daily for 2 wk. Maintenance: 100-200 mg once daily or in 2 divided doses. Childn 2-12 yr Add-on therapy w/ Na valproate 0.15 mg/kg/day once a day for 2 wk, then 0.3 mg/kg/day once a day for 2 wk. May be increased by 0.3 mg/kg increments every 1-2 wk to achieve a maintenance dose of 1-5 mg/kg (once a day or 2 divided doses) to max 200 mg/day. Add-on therapy w/ phenytoin, carbamazepine, primidone & phenobarb 0.6 mg/kg, then 1.2 mg/kg. To be given in 2 divided doses for 2 wk. May be increased by 1.2 mg/kg increments every 1-2 wk to achieve a maintenance dose of 5-15 mg/kg (once a day or 2 divided doses) to max 400 mg/day. Add-on therapy w/ drugs that do not significantly inhibit or induce lamotrigine glucuronidation 0.3 mg/kg, then 0.6 mg/kg. To be given in 1 or 2 divided doses for 2 wk. May be increased by 0.6 mg/kg increments every 1-2 wk to achieve a maintenance dose of 1-10 mg/kg (once a day or 2 divided doses) to max 200 mg/day.
Click to view Lamictal detailed prescribing infomation |
|
Overdosage |
View Lamictal overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (Swallow whole, do not chew/crush.). |
|
Contraindications |
[Click for Lamictal detailed prescribing infomation] |
|
Special Precautions |
History of allergy/rash to other antiepileptic drugs. Renal failure. Monitor for clinical worsening & suicidality. Avoid abrupt w/drawal (reduce dosage stepwise over a period of 2 wk). Pregnancy & lactation. Childn <2 yr.
Click to view Lamictal detailed prescribing infomation |
|
Adverse Drug Reactions |
Skin rash, headache, agitation, somnolence, dizziness, arthralgia, pain, back pain, ataxia, diplopia, blurred vision, nausea, vomiting, aggression, irritability, insomnia, tremor, nystagmus, diarrhoea, tiredness.
View ADR Monitoring Form |
|
Drug Interactions |
Enhanced metabolism w/ phenytoin, carbamazepine, phenobarb, primidone. Reduced metabolism w/ Na valproate. Decreased efficacy of hormonal contraceptive.
View more drug interactions with Lamictal |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Lamictal storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Lamictal description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Lamictal mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
